Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Nanomedicine. 2019 Nov 26;24:102127. doi: 10.1016/j.nano.2019.102127

Figure 3. MXD3 ASO-SHA NP complexes show a dose-dependent MXD3 knockdown in SK-N-DZ cells.

Figure 3.

(A) Immunocytochemistry and (B) relative MFI 8 hours after treatment (n=6, **p<0.01, ***p<0.001).

(C) Living cell count 4, 8, 24, 48 and 72 hours after treatment. (n=6, ****p<0.0001)